E
EPIMED GmbH | Berlin, Germany
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Ritonavir
Emtricitabine
Tipranavir
Elvitegravir
Tenofovir Disoproxil Fumarate
Tenofovir
Rilpivirine
Milvexian
Apricitabine
JNJ-73763989
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
1 of 16 total trials
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian
Trial sponsors
A
B
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems